0.95 USD
+0.06 (+6.74%)
Taking everything into account, DYAI scores 2 out of 10 in our fundamental rating. DYAI was compared to 525 industry peers in the Biotechnology industry. DYAI may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, DYAI is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- DYAI had negative earnings in the past year.
- DYAI had a negative operating cash flow in the past year.
- DYAI had negative earnings in each of the past 5 years.
- DYAI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- DYAI has a Return On Assets (-62.95%) which is comparable to the rest of the industry.
- DYAI has a worse Return On Equity (-281.84%) than 72.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -62.95% | ||
| ROE | -281.84% | ||
| ROIC | N/A |
ROA(3y)-70.74%
ROA(5y)-60.92%
ROE(3y)-146.19%
ROE(5y)-108.49%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of DYAI (31.54%) is better than 73.14% of its industry peers.
- DYAI's Gross Margin has improved in the last couple of years.
- The Profit Margin and Operating Margin are not available for DYAI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 31.54% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y50.87%
GM growth 5Y38.12%
2. Health
2.1 Basic Checks
- Compared to 1 year ago, DYAI has more shares outstanding
- Compared to 5 years ago, DYAI has more shares outstanding
- DYAI has a worse debt/assets ratio than last year.
2.2 Solvency
- DYAI has an Altman-Z score of -9.86. This is a bad value and indicates that DYAI is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -9.86, DYAI is doing worse than 71.81% of the companies in the same industry.
- DYAI has a Debt/Equity ratio of 1.92. This is a high value indicating a heavy dependency on external financing.
- DYAI's Debt to Equity ratio of 1.92 is on the low side compared to the rest of the industry. DYAI is outperformed by 78.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.92 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.86 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- DYAI has a Current Ratio of 2.85. This indicates that DYAI is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 2.85, DYAI is doing worse than 66.29% of the companies in the same industry.
- A Quick Ratio of 2.85 indicates that DYAI has no problem at all paying its short term obligations.
- The Quick ratio of DYAI (2.85) is worse than 64.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.85 | ||
| Quick Ratio | 2.85 |
3. Growth
3.1 Past
- DYAI shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.35%.
- Looking at the last year, DYAI shows a decrease in Revenue. The Revenue has decreased by -0.66% in the last year.
- DYAI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.78% yearly.
EPS 1Y (TTM)-4.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
Revenue 1Y (TTM)-0.66%
Revenue growth 3Y13.35%
Revenue growth 5Y15.78%
Sales Q2Q%-40.47%
3.2 Future
- The Earnings Per Share is expected to grow by 18.00% on average over the next years. This is quite good.
- The Revenue is expected to grow by 58.83% on average over the next years. This is a very strong growth
EPS Next Y-14.75%
EPS Next 2Y21.02%
EPS Next 3Y18%
EPS Next 5YN/A
Revenue Next Year-10.33%
Revenue Next 2Y31.23%
Revenue Next 3Y17.64%
Revenue Next 5Y58.83%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- DYAI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year DYAI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as DYAI's earnings are expected to grow with 18.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.02%
EPS Next 3Y18%
5. Dividend
5.1 Amount
- No dividends for DYAI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:DYAI (1/22/2026, 12:07:45 PM)
0.95
+0.06 (+6.74%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-24 2026-03-24/amc
Inst Owners17.12%
Inst Owner Change0%
Ins Owners14.79%
Ins Owner Change2.91%
Market Cap34.38M
Revenue(TTM)3.34M
Net Income(TTM)-7.35M
Analysts82.86
Price Target7.14 (651.58%)
Short Float %0.74%
Short Ratio0.73
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.9%
Min EPS beat(2)-35.76%
Max EPS beat(2)1.96%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)30.92%
Min Revenue beat(2)3.83%
Max Revenue beat(2)58.01%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)40%
PT rev (3m)-22.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-125%
EPS NY rev (1m)0%
EPS NY rev (3m)-28.57%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-20.99%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-16.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 10.29 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 13.19 | ||
| P/tB | 13.19 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.24
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS0.09
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -62.95% | ||
| ROE | -281.84% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 31.54% | ||
| FCFM | N/A |
ROA(3y)-70.74%
ROA(5y)-60.92%
ROE(3y)-146.19%
ROE(5y)-108.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y50.87%
GM growth 5Y38.12%
F-Score2
Asset Turnover0.29
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.92 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.85 | ||
| Quick Ratio | 2.85 | ||
| Altman-Z | -9.86 |
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
EPS Next Y-14.75%
EPS Next 2Y21.02%
EPS Next 3Y18%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.66%
Revenue growth 3Y13.35%
Revenue growth 5Y15.78%
Sales Q2Q%-40.47%
Revenue Next Year-10.33%
Revenue Next 2Y31.23%
Revenue Next 3Y17.64%
Revenue Next 5Y58.83%
EBIT growth 1Y-9.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.12%
OCF growth 3YN/A
OCF growth 5YN/A
DYADIC INTERNATIONAL INC / DYAI FAQ
What is the ChartMill fundamental rating of DYADIC INTERNATIONAL INC (DYAI) stock?
ChartMill assigns a fundamental rating of 2 / 10 to DYAI.
Can you provide the valuation status for DYADIC INTERNATIONAL INC?
ChartMill assigns a valuation rating of 0 / 10 to DYADIC INTERNATIONAL INC (DYAI). This can be considered as Overvalued.
What is the profitability of DYAI stock?
DYADIC INTERNATIONAL INC (DYAI) has a profitability rating of 1 / 10.